Mohamed Abd El-Motaleb Abd El-Rahman

Mohamed Abd El-Motaleb Abd El-Rahman

Auto-generated profile, based on publicly available information

Mohamed Abd El-Motaleb Abd El-Rahman

Atomic Energy Authority

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2016 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
MMM. A. Motaleb
M. A. Motaleb
AAA. S. A. Adli
A. S. A. Adli
MEM. El-Tawoosy
M. El-Tawoosy
MSM. H. Sanad
M. H. Sanad
MAM. AbdAllah
M. AbdAllah

6 June 2017 in Journal of Radioanalytical and Nuclear Chemistry
Verified
Journal Article
Closed access
PDF file
MMM. A. Motaleb
M. A. Motaleb
ASAdli Selim
Adli Selim
MEM. El-Tawoosy
M. El-Tawoosy
MSM. H. Sanad
M. H. Sanad
MEM. A. El-Hashash
M. A. El-Hashash

16 April 2018 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
MMM. A. Motaleb
M. A. Motaleb
ASAdli Selim
Adli Selim
MEM. El-Tawoosy
M. El-Tawoosy
MSM. H. Sanad
M. H. Sanad
MEM. A. El-Hashash
M. A. El-Hashash
Purpose: Dioxime derivative is reported to exhibit high affinity towards tumor cells. The objective of the present study is to synthesize a new dioxime derivative to be labeled with technetium-99m for using as a solid tumor marker. Materials and methods: ((2E,2′,3E,3′)-3,3′-(cyclohexane-1,2-diylbis (azanylylidene)) bis-(butan-2-one)dioxime) was synthesized by condensation of Butan-2,3-dione monooxime and diaminocyclohexane and labeled with 99mTc. The in-vivo distribution of the agent was studied by carrying out biodistribution in tumor bearing Albino mice. Results: A new cyclohexane dioxime derivative was synthesized with a good yield of 93 ± 2% and its complexation with 99mTc was prepared with 85 ± 4% radiochemical yield under the optimized conditions and the preparation exhibited in-vitro stability up to 6 h. Biodistribution studies showed high uptake in tumor cells with T/NT (target to non-target ratio) = 3.4 ± 0.2 after 0.5 h post injection. Conclusion: As a result of biodistribution studies, the newly synthesized cyclohexane dioxime derivative showed its good uptake in tumor cells, which affords a potential radiopharmaceutical that could be used as a good tumor imaging agent.

30 November 2019 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
HFHend Fayez
Hend Fayez
MEMohamed Abd El‐Motaleb
Mohamed Abd El‐Motaleb
ASAdli Selim
Adli Selim

28 November 2016 in BMC Chemistry
Verified
Journal Article
Open access
PDF file
RAReem Ibrahim Al-Wabli
Reem Ibrahim Al-Wabli
TSTamer Sakr
Tamer Sakr
MKMohammed Khedr
Mohammed Khedr
ASAdli Selim
Adli Selim
MEMohamed Abd El-Motaleb Abd El-Rahman
Mohamed Abd El-Motaleb Abd El-Rahman
WZWafaa Zaghary
Wafaa Zaghary
One of the most popular techniques for cancer detection is the nuclear medicine technique. The present research focuses on Platelet-12-lipoxygenase (P-12-LOX) as a promising target for treating and radio-imaging tumor tissues. Curcumin was reported to inhibit this enzyme via binding to its active site. A novel curcumin derivative was successfully synthesized and characterized with yield of 74%. It was radiolabeled with the diagnostic radioisotope technetium-99m with 84% radiochemical yield and in vitro stability up to 6 h. The biodistribution studies in tumor bearing mice confirmed the high affinity predicted by the docking results with a free binding energy value of (ΔG −50.10 kcal/mol) and affinity (13.64 pki) showing high accumulation in solid tumor with target/non-target ratio >6. The newly synthesized curcumin derivative, as a result of a computational study on platelet-12 lipoxygenase, showed its excellent free binding energy (∆G −50.10 kcal/mol) and high affinity (13.64 pKi). It could be an excellent radio-imaging agent that targeting tumor cells via targeting of P-12-LOX.

23 February 2016 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
MMM. A. Motaleb
M. A. Motaleb
III. T. Ibrahem
I. T. Ibrahem
VAV. R. Ayoub
V. R. Ayoub
AGA. S. Geneidi
A. S. Geneidi